12-step Facilitation for the Dually Diagnosed (TSFDD)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Michael Bogenschutz, University of New Mexico
ClinicalTrials.gov Identifier:
NCT00583440
First received: December 20, 2007
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

This is a randomized trial testing the efficacy of a modified 12-step facilitation therapy for individuals with serious mental illness and alcohol use disorders, compared to usual treatment. 135 participants are randomized in 2:1 ratio to the modified 12-step facilitation (12 sessions of individual counseling) vs. treatment as usual. The primary hypothesis is that those receiving 12-step facilitation will have better drinking outcomes (percent days abstinence and drinks per drinking day)at end of treatment.


Condition Intervention Phase
Alcoholism
Diagnosis, Dual (Psychiatry)
Behavioral: 12-step facilitation
Behavioral: Treatment as usual
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: 12-step Facilitation for the Dually Diagnosed

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • Percent days abstinent from alcohol [ Time Frame: 12, 24, 36, and 48 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Drinks per drinking day [ Time Frame: 12, 24, 36, and 48 weeks ] [ Designated as safety issue: No ]
  • 12-step participation [ Time Frame: 12, 24, 36, and 48 weeks ] [ Designated as safety issue: No ]

Enrollment: 121
Study Start Date: September 2005
Study Completion Date: May 2011
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Behavioral: 12-step facilitation
12 weekly individual 12-step facilitation sessions
Active Comparator: 2 Behavioral: Treatment as usual
Usual clinical treatment in a dual diagnosis treatment program

Detailed Description:

Although there has been relatively little work on 12-step treatment for seriously mentally ill patients, extant literature indicates that dually diagnosed individuals attend traditional 12-step programs such as AA, NA, and CA at rates comparable to singly diagnosed substance abusers, and that participation is associated with decreases in substance use. Specialized 12-step programs for the dually diagnosed, developed over the past 10 years, may offer additional benefits. In order to maximize the effectiveness of specialized and traditional 12-step programs for dually diagnosed individuals, specially adapted 12-step facilitation (TSF) treatment for the dually diagnosed should be developed and tested. Standard TSF should be modified to address the special needs of dually diagnosed individuals, mesh with specialized 12-step programs available in the area, and address barriers to attendance, participation, and engagement experienced by the dually diagnosed. We have developed a modified TSF based on the Project MATCH TSF manual. Modifications to this 12 week individual therapy include: emphasis on specialized 12-step program attendance; readings primarily from specialized 12-step program literature; participation in the second session by a community specialized 12-step program member; case management to assist participants in finding and attending meetings; omission of work on the fourth step; and the addition of topics covering medication compliance and specific social skills needed to negotiate 12-step meetings. In a pilot study with 10 dually diagnosed individuals, participants showed significant decreases in substance use and significant increases in 12-step attendance after receiving the specialized TSF. Building on this pilot study, the proposed study is a larger Stage 1b study of the modified TSF for seriously mentally ill patients engaged in dual diagnosis treatment. Participants with a psychotic or major affective disorder will be randomized to modified TSF (n=90) vs. treatment as usual (n=45). Participants will be followed for a total of 48 weeks. Assessments will include rigorous diagnosis and measures of alcohol and other drug use, consequences, psychiatric symptoms, 12-step behaviors, 12-step specific and non-specific change mechanisms, and social support. Specific Aims of the study include assessment of the integrity of the planned intervention and assessment battery; tests of the effectiveness of the adapted TSF relative to treatment as usual; determination of whether psychiatric diagnosis moderates treatment response; and investigation of causal mechanisms of response to treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. SCID Diagnosis of a psychotic disorder (schizophrenia, schizoaffective disorder, or psychosis not otherwise specified) or a major affective disorder (major depression, bipolar disorder, or depressive disorder not otherwise specified, provided in the latter case that criteria have been met for a major depressive episode).
  2. SCID diagnosis of alcohol abuse or dependence which is active within the past 1 month (i.e., not in early or sustained full remission).
  3. Two or more days of heavy drinking (5 or more drinks for per occasion for a man, 4 or more drinks per occasion for a woman) in the 30 days prior to screening.
  4. Willingness to participate in specialized 12-step programs.
  5. Ability to provide informed consent.
  6. Ability to read, speak, and understand English at least the 5th grade level.
  7. Ability to provide at least one contact person to assist in tracking for follow-up assessment.

Exclusion Criteria:

  1. Current attendance of any 12-step program (two or more 12-step meetings in the past month).
  2. Unstable psychiatric illness, defined by psychiatric hospitalization in the past 1 month; more than 3 hospitalizations in the past year; or psychosis or mania which would render the individual incapable of informed consent.
  3. Active suicidality (any clinically significant suicide attempts in the past 3 months or any current suicidal intent or definite plan).
  4. Current homicidal ideation aimed at a specific person or persons.
  5. Medical illness which is severe enough to compromise participation in the study.
  6. Mental retardation, dementia, or other cognitive impairment of sufficient severely to render the individual incapable of informed consent or incapable of comprehending and participating in the TSF therapy or 12-step meetings.
  7. Expectation of being out of town or in jail for more than 21 days during the treatment period.
  8. Expectation of participation in any other formal addiction treatment during the study period (not including TAU, 12-step or other mutual support groups).
  9. Current engagement in behavioral health treatment (including case management) at another facility.
  10. Current engagement in non-TAU treatment at UNMPC, such as psychotherapy, intensive outpatient treatment, or MET.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00583440

Locations
United States, New Mexico
UNM HSC Department of Psychiatry Clinical Trials
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Michael P. Bogenschutz, MD University of New Mexico Health Sciences Center
  More Information

No publications provided by University of New Mexico

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael Bogenschutz, Professor of Psychiatry, University of New Mexico
ClinicalTrials.gov Identifier: NCT00583440     History of Changes
Other Study ID Numbers: NIAAA-Bogenschutz-AA015419, R01AA015419, NIH Grant 1R01 AA015419
Study First Received: December 20, 2007
Last Updated: January 28, 2013
Health Authority: United States: Federal Government

Keywords provided by University of New Mexico:
12-step
mutual help
dual diagnosis
serious mental illness

Additional relevant MeSH terms:
Alcoholism
Alcohol-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on October 29, 2014